Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus (Nasdaq: SLP) announced a funded research collaboration with Lonza and the U.S. FDA to develop and validate a mechanistic predictive framework for amorphous solid dispersion (ASD) oral products.
The program pairs Lonza's advanced in vitro dissolution testing with Simulations Plus' DDDPlus and GastroPlus platforms to build IVIVE and virtual bioequivalence methods, aiming to improve prediction of food and elevated gastric pH effects and potentially reduce reliance on certain clinical bioequivalence studies while aligning with regulatory MIDD priorities.
Simulations Plus (Nasdaq: SLP) completed its 2026 Spring School March 23–27, 2026, training over 1,400 scientists from more than 65 countries in model-informed drug development (MIDD).
The week-long program offered GastroPlus and MonolixSuite tracks with lectures, hands-on exercises, and live Q&A to broaden applied modeling expertise globally.
Simulations Plus (Nasdaq: SLP) reported Q2 fiscal 2026 results: revenue $24.3M (+8% YoY), software $14.6M (60%), services $9.7M (40%). Gross profit was $16.1M (66%). Net income was $4.5M; diluted EPS $0.22. Adjusted EBITDA was $8.7M (36% of revenue).
Six-month revenue was $42.7M (+3%). Management lowered fiscal 2026 adjusted diluted EPS guidance to $0.75–$0.85 due to an increased expected effective tax rate of 23–25%. Revenue guidance remains $79M–$82M.
Simulations Plus (Nasdaq: SLP) will report second quarter fiscal 2026 results after the market close on Thursday, April 9, 2026, with a management conference call the same day at 5:00 p.m. ET.
Investors can join a live webcast via the company investor relations site, dial domestic or international conference numbers, or use a Call me™ return-call link; a replay will be available about one hour after the call.
Simulations Plus (Nasdaq: SLP) announced strategic collaboration programs with three large pharmaceutical companies to advance AI-enabled, model-informed drug development workflows.
The programs will integrate the company’s AI agents into its platforms (GastroPlus®, MonolixSuite™, ADMET Predictor®, Thales™) to enable natural-language interaction, automated data processing, coordinated simulations, and governance standards for enterprise deployment.
Simulations Plus (Nasdaq: SLP) convenes industry and regulatory leaders for a panel, “From Debate to Deployment: Responsible, Practical AI in MIDD,” on March 5, 2026 at the ASCPT Annual Meeting in Denver.
Panelists will discuss current AI use in model‑informed drug development, build vs buy decisions, regulatory principles, and human roles in AI integration.
Simulations Plus (Nasdaq: SLP) announced extensions of two research collaborations with the U.S. Food and Drug Administration and the National Institute of Environmental Health Sciences. The projects advance AI-enabled computational toxicity models and new approach methodologies (NAMs) for food, chemical, and environmental safety assessment. The FDA extension expands access to curated toxicological datasets for further training, validation, and benchmarking of Simulations Plus’ AI/ML models. The NIEHS extension continues application of the company’s software to design, validate, and benchmark experimental systems under national chemical safety modernization efforts.
Simulations Plus (Nasdaq: SLP) announced CEO Shawn O’Connor will participate in multiple investor conferences in February–March 2026, including BTIG (Feb 10, Snowbird, UT), TD Cowen (Mar 3, Boston, MA) and KeyBanc (Mar 18, virtual).
Formats include one-on-one meetings and fireside chats; webcast links will be available on the company Investor Relations site.
Simulations Plus (Nasdaq: SLP) hosted a 2026 Virtual Investor Day on January 21, 2026, outlining its strategy to evolve from best-in-class tools into an integrated, AI-enabled modeling ecosystem for drug development.
The company emphasized alignment with FDA and EMA principles for good AI practice, combining mechanistic modeling, AI-assisted workflows, cloud execution, and regulator-ready reproducibility to address rising scientific complexity and demand for in silico evidence.
Executive leaders highlighted priorities: validated science, transparency, traceability, and enterprise infrastructure to support customers and regulators.
Simulations Plus (Nasdaq: SLP) reported Q1 FY2026 results for the quarter ended Nov 30, 2025: total revenue $18.4M (down 3% YoY), software revenue $8.9M (down 17%), services revenue $9.5M (up 16%). Gross profit was $10.9M with gross margin 59% (versus 54% prior year). GAAP net income was $0.7M (diluted EPS $0.03); adjusted net income was $2.6M (adjusted diluted EPS $0.13). Adjusted EBITDA was $3.5M (19% of revenue). The company reaffirmed FY2026 guidance: revenue $79M–$82M, software mix 57–62%, adjusted diluted EPS $1.03–$1.10, and adjusted EBITDA margin 26–30%. A virtual Investor Day is scheduled for Jan 21, 2026.